Advanced Filters
noise

Uterine Cancer Clinical Trials

A listing of Uterine Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 508 clinical trials
Y Yuanming Shen, Dr

Chemo-immunotherapy for Cervical Cancer Stage IIICp Trial

Efficacy evaluation of camrelizumab combined with chemotherapy for adjuvant treatment of patients with pathologically confirmed lymph node-positive cervical cancer after staging surgery.

18 - 70 years of age Female Phase 2
A Anissa Megzari

Prognostic Role of Inhibitor of Apoptosis Protein Overexpression on Recurrence Rate in Cervical Cancer

Overexpression of inhibitors of apoptosis proteins (IAPs) in patients treated for locally advanced cervical cancer with exclusive radio-chemotherapy may have a prognostic role on the local recurrence rate at 24 months.

18 years of age Female Phase N/A
G Gwenn LE GALL, Medical Doctor

Collection of Endometrial Cancer-derived Organoids to Evaluate the Efficacy of PARP Inhibitors: PENDOR Pilot Study

This study comprises 3 stages: Collection of tumor and blood samples. Creation of organoid models based on tumor samples. Development of functional tests to predict clinical response to treatment.

18 years of age Female Phase N/A

An Observational Study of Molecular profIling of Advanced and aggRessive ENdometrial Cancer and 1-st Line Treatment Approaches in Russian Federation

Multicenter, observational, prospective study of molecular profiling in advanced and aggressive endometrial cancer patients and 1-st line treatment approaches in Russian Federation

18 years of age Female Phase N/A
C Caitlin Eggleston

Vaginal Cuff Brachytherapy Fractionation Study

The purpose of this study is to see the effects of two different standard of care treatments of endometrial cancer on sexual dysfunction. This study will compare two standard of care treatments: HDR (high dose radiation) vaginal brachytherapy 3 fractions of 7 Gy to HDR vaginal brachytherapy 6 fractions of …

18 years of age Female Phase 3
S Site Public Contact

Study of Pelvic Hypofractionated Radiotherapy in Endometrial Cancer

This study will investigate if a shorter treatment course (known as "hypofractionation") for pelvic radiation is safe for women with endometrial cancer. Doctors leading the study will also determine the safest and most tolerable dose of shortened radiation (hypofractionation) used to treat women in this study. Because this study will …

18 years of age Female Phase 1/2

Molecular Classification in Mexican Patients With Endometrial Cancer and Its Impact on Prognosis

Endometrial cancer (EC) is one of the most common gynecological neoplasms, being the second in incidence and third in mortality in Mexico. Recent studies show that EC molecular classification (Cancer Genome Atlas Research Network, 2013) serves to establish a more accurate prognosis in these patients and regulate therapeutic behavior in …

18 years of age Female Phase N/A
G Gregor Sersa, PhD

Electrochemotherapy of Gynecological Cancers

To determine the effectiveness, feasibility and safety of electrochemotherapy in treatment of local and/or regional recurrences of gynecological cancers with electrochemotherapy in which standard treatment options have been exhausted.

18 - 105 years of age Female Phase 2

Weight Management in Overweight Endometrial Cancer Patients Undergoing Fertility-sparing Treatment

In this study, overweight and obese patients with endometrial cancer treated with fertility- sparing therapy were randomly divided into two groups. The test group was given weight management, while the control group was given routine care. Relevant information such as body morphology and composition, glycolipid metabolism, molecular typing and tumor …

18 years of age Female Phase N/A
A Aknar Calabrich

Nivolumab-ipilimumab and Chemoradiation for Cervical Cancer

A total of 112 patients with locally advanced cervical cancer will be randomized 1:1 to standard therapy with cisplatin-based chemoradiation or nivolumab-ipilimumab induction followed by cisplatin-based chemoradiation. The primary outcome will be 3-year disease-free survival.

18 - 95 years of age Female Phase 2

Simplify language using AI